Legal Representation
Attorney
Sarah Anne Keefe
USPTO Deadlines
Application History
36 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 27, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Jun 27, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Jun 3, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 2, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Mar 10, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Mar 9, 2025 | IUAF | S | USE AMENDMENT FILED |
| Sep 27, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Sep 27, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Sep 27, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
| Sep 27, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 3, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 2, 2024 | EXT2 | S | SOU EXTENSION 2 FILED |
| Apr 2, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 2, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Sep 29, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sep 27, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
| Sep 27, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Sep 27, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Apr 4, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Feb 7, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Feb 7, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 18, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jan 3, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Dec 23, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Dec 22, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Dec 22, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Nov 30, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Nov 30, 2022 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Nov 30, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Nov 30, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 25, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jul 25, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jul 25, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jul 20, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Nov 11, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 18, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Pharmaceutical research and development in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, targeted genomic insertion, targeted genomic integration, genetic diseases, gene therapy and cell therapy; Medical laboratory services in the nature of gene editing for developing cells and protein RNA complexes for medical use
First Use Anywhere:
Mar 1, 2022
First Use in Commerce:
Mar 1, 2022
Classification
International Classes
042